This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PRXMET, PRX MET, PRX-MET, PRXOTC, PRX OTC
Description: PRX-OTC is an mRNA with an undisclosed method of action, developed by PhaseRx using its SMARTT polymer technology. SMARTT utilizes novel synthetic polymers that deliver mRNA drugs into the cytoplasm where they can be translated into the desired protein of interest.
Additional information available to subscribers only: